Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Key Highlights
- ➤Erasca (ERAS) schedules November 20 virtual event on updated ERAS-0015 Phase 1 data
- ➤ERAS-0015 showed confirmed partial responses at doses as low as 8 mg once daily
- ➤ERAS-0015 produced responses across multiple tumor types and RAS mutations
- ➤ERAS-4001 demonstrated preclinical tumor regression across multiple KRAS-mutant models
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.
The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18–20 in Barcelona, Spain.
Get started
Create a free account to read the full story.
